Fintel reports that on November 21, 2025, Piper Sandler reiterated coverage of Moderna (NasdaqGS:MRNA) with a Overweight ...

Fintel reports that on November 21, 2025, Leerink Partners maintained coverage of Moderna (NasdaqGS:MRNA) with a Underperform ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

In addition to Barclays, Moderna also received a Hold from Berenberg Bank’s Harry Gillis in a report issued on November 14. However, yesterday, Wolfe Research reiterated a Sell rating on Moderna ...

In addition to Evercore ISI, Moderna also received a Hold from Needham’s Joseph Stringer in a report issued today. However, on the same day, Leerink Partners maintained a Sell rating on Moderna ...